It is normal to have a lot of questions before you decide whether or not to take part in a clinical study.
No FAQs found for this country.
References:
1. Hoyler TF, Strasser DS, Berkani O, et al. LO-016 The multifaceted immunomodulatory properties of cenerimod, a selective S1P1 receptor modulator, target three
key aspects of SLE pathogenesis. Lupus Sci Med. 2023;10.
2. Gerossier E, Nayar S, Froidevaux S, et al. Cenerimod, a selective S1P1 receptor modulator, improves
organ-specific disease outcomes in animal models of Sjögren's syndrome. Arthritis Res Ther. 2021;23(1):289.
3. Askanase A, D’Cruz D, Kalunian K, et al. Efficacy and safety of cenerimod in patients with moderate to severe systemic lupus erythematosus (SLE): A multicenter, randomized, parallel-group, double-blind, placebo-controlled, dose-finding phase 2b trial. Arthritis Rheumatol. 2022;74(Suppl 9):3293–3297.
4. Hermann V, Batalov A, Smakotina S, Juif PE, Cornelisse P. First use of cenerimod, a selective S1P1 receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study. Lupus Sci Med. 2019 Nov 9;6(1):e000354.
5. The basics. NIH Clinical Research Trials and You. Available at: The Basics | National Institutes of Health (NIH). Accessed Nov 2024.